Table 2.
Studies evaluating screening for liver fibrosis in diabetic patients using transient elastography.
| Kwok 201526 | Roulot 201729 | Lai 201928 | Sporea 202027 | |
|---|---|---|---|---|
| Country | China | France | Malaysia | Romania |
| Population | T2DM | Newly diagnosed T2DM | T2DM | T2DM |
| Patients | ≥18 years | ≥18 years | ≥18 years | ≥18 years |
| Sample size (n) | 1,884 | 669 | 557 | 534 |
| Target | TE ≥9.6 kPa (M probe) or ≥9.3 kPa (XL probe) | TE ≥9.6 kPa | TE ≥9.6 kPa (M probe) or ≥9.3 kPa (XL probe) | TE ≥9.7 kPa |
| FibroScan probe used | XL probe if M probe failure | XL probe if M probe failure | M or XL probe according to manufacturer recommendations | XL probe if BMI ≥30 kg/m2 or skin-to-capsule distance >25 mm |
| Prevalence (%) | 17.7% | 7.3% | 21.0% | 19.5% |
| Independent predictors of the target | Diabetes duration ALT BMI HDL-cholesterol Urine ACR |
Age ALT BMI GGT |
ALT GGT HDL-cholesterol Platelets |
AST |
| Liver biopsy (n) | 94 | 47 | 57 | – |
| Fibrosis stage (n) a: | ||||
| 0 | 5 | F0-2: 23 | – | – |
| 1 | 29 | – | – | – |
| 2 | 13 | – | – | – |
| 3 | 20 | 16 | F3-4: 23 | – |
| 4 | 27 | 8 | – | – |
ACR, albumin-creatinine ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; T2DM, type 2 diabetes mellitus.
a
According to the NASH CRN staging system.